As more patents make their way through IPRs, the balance of how the pharmaceutical industry selects between IPRs and district court litigation will likely evolve.
Erica Pascal
Advertisement
Dr. Erica Pascal is a partner in DLA Piper’s Patent Litigation practice
Articles by Erica Pascal
Advertisement
Latest Updated Articles
- Are IPRs Impacting the Pharmaceutical Industry?
July 24th 2015
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
2
Regulatory Roundup—October 2026: FDA Advances Rare Disease Development and Transparency Efforts
3
Expansions and Strategies Showcased and Gained at CPHI Milan 2026
4
AAPS PharmSci 360: How USP Is Tackling the Novel Excipient Roadblock
5